Neuphoria Therapeutics Inc. (NEUP)

Nasdaq: NEUP · Pharmaceutical Preparations · Burlington, MA · filing with the SEC since 2002

Full chart Alerts Compare

Grade4.5

◀ Past 3.5● Present 4.4▶ Future 5.1

5 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2026, as filed

Revenue$1.2M-92.5%

Net income-$13.5M-3539.3%

Earnings per share$-3.06-1230.4%

Operating cash flow-$12.4M-16095.4%

Cash$19.9M+39.0%

Debtn/a

Shareholders’ equity$24.6M+29.5%

Shares, diluted4,395,776+170.9%

Return on equity-54.7%

The recordfrom its filings

Filings in 202618

Newest filingOct 23 · 8-K

Annual reportSep 18, 2026

Quarterly reportMay 15, 2026

Next report due10-Q by Nov 14

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted63

Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Trailing twelve months to Jun 2026Net income -$13.5MCash from operations -$12.4Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

23242526

As filed, in USD. Nothing here is a forecast.

News

Oct 23, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 5, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Sep 18, 2026 · SEC EDGAR · Form 10-K

Annual report

Open the filing on sec.gov

Sep 18, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Sep 18, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Sep 18, 2026 · SEC EDGAR · Form DEF 14A

Proxy statement

Open the filing on sec.gov

Jul 28, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Jul 24, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Jul 24, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

May 26, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Neuphoria Therapeutics Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Burlington, MA.

Newest on the record

Current report on Oct 23. Before it, large holder notice on Oct 5.

What is due next

The 10-Q for the period to Sep 30, 2026, due by Nov 14, 2026.

About NEUP

Neuphoria Therapeutics Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Burlington, MA. In its latest annual figures on file, for the fiscal year ended 2026-06-30, it reported revenue of $1.2 million and a loss of $13 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersBurlington, MA

Business modelPre-revenue company

ExchangeNasdaq

Filing since2002

Fiscal year endsJun 30

SEC number (CIK)1191070

Peers on fileSKYE, TLPH, VERU, SLGL

Who runs it

Financial performance

In fiscal 2026 Neuphoria Therapeutics’s revenue was $1.17 million, down 92.5% from $15.65 million the year before. It made a net loss of $13.45 million.

Annual report, filed Sep 18, 2026.

Financial statements

The grade

Neuphoria Therapeutics grades 4.5 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Four of the nine metrics are read as filed and five are SI estimates, each with its reasoning.

◀ Past3.5

● Present4.4

▶ Future5.1

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton NEUP · research, not advice